Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

NCT03834506 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1030

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Docetaxel
DRUG: Prednisone
DRUG: Placebo
DRUG: Dexamethasone

Sponsor

Merck Sharp & Dohme LLC